Overview of TOMI Environmental Solutions, Inc.
TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) is a prominent company that specializes in advanced disinfection and decontamination solutions, primarily through its innovative Binary Ionization Technology® (BIT™). In its recent financial report for Q3 2025, the company showcased impressive financial results and strategic initiatives geared towards generating long-term growth.
Q3 2025 Financial Highlights
In the third quarter of 2025, TOMI achieved remarkable financial highlights, demonstrating a solid trajectory for future growth:
- Strong Revenue Growth: The company reported revenues of $2.0 million, reflecting a staggering 95% sequential increase compared to Q2 2025, fueled by enhanced equipment purchases and robust sales of BIT™ Solutions.
- High Gross Margins: TOMI maintained a gross profit margin of 61%, highlighting operational efficiency and the intrinsic value of its technology.
- Cost Management: The company successfully reduced selling, research, and administrative expenses, showcasing disciplined cost management.
- International Expansion: Approximately 36% of Q3 revenue was generated from international markets, a significant increase from 20% in Q2 2025, indicating TOMI's growing global footprint.
- Ongoing Product Innovation: The company continues investing in research and development to broaden applications of SteraMist® across various sectors, including life sciences and healthcare.
Financial Performance Comparison
When comparing results from September 30, 2025, to the same period in 2024, the apparent shifts in sales reflect broader economic dynamics:
- Net sales were recorded at $2,012,000 for Q3 2025, compared to $2,542,000 in Q3 2024. For the first nine months, net sales were $4,619,000 versus $6,670,000 for the same period in the previous year.
- SteraMist solution sales saw a year-over-year increase of 21% for nine months ended September 30, 2025.
- While the gross profit margins held steady at 61%, operating loss for Q3 2025 was $(321,000), contrasting with income from operations of $149,000 in Q3 2024.
- This resulted in a net loss of $(450,000) or $(0.02) per share for Q3 2025, compared to a net income of $59,000 for the same period in 2024.
Strategic Business Developments
The quarter was marked by various strategic initiatives aimed at enhancing TOMI’s market position:
- The sales order backlog increased to $0.9 million by quarter-end and surged to $1.3 million by October 31, with pending contracts expected to finalize before the year's end.
- The estimated potential demand for TOMI's product offerings, including Custom Engineered System, Hybrid Solutions, and SteraMist, totals approximately $15 million, with $7 million classified as high-priority opportunities.
- TOMI successfully completed notable installations, proving the scalability of SteraMist® technology and optimizing installations in diverse environments, notably in the pharmaceutical sector.
- Recent partnerships further solidify TOMI's presence in academia and healthcare, with significant technology deployments anticipated in the upcoming period.
- On September 18, 2025, the FDA broadened the permitted use of Hydrogen Peroxide, opening expansive opportunities for the application of SteraMist iHP technology.
Financial Management and Liquidity Position
As of September 30, 2025, TOMI reported $2.5 million in working capital. Operational cash needs have improved, resulting in a significant reduction in cash used compared to the previous year. Moreover, the company recently secured $535,000 through convertible note financing to bolster its capital resources.
The establishment of an equity line of credit enables TOMI to sell up to $20 million in common stock over a 24-month period, enhancing financial flexibility to support growth initiatives. A universal shelf registration statement is anticipated, allowing for the sale of up to $50 million in securities to meet operational needs.
Looking Forward
TOMI is entering the final quarter of 2025 with a robust operational framework, looking to capitalize on clean manufacturing and biosecurity trends. The strategic focus includes:
- Expanding recurring service contracts and exploring new service offerings.
- Driving steady year-over-year revenue growth by enhancing SteraMist solution sales.
- Increasing international market penetration via targeted marketing campaigns.
- Forming additional partnerships with governmental and institutional sectors.
- Enhancing financial management to maintain a resilient balance sheet.
- Strengthening team capabilities to support these growth dynamics.
Conference Call and Additional Information
TOMI will host a conference call to discuss the Q3 2025 results, reflecting on progress, strategies, and future goals.
Frequently Asked Questions
What were the key financial highlights for TOMI in Q3 2025?
TOMI reported a 95% revenue growth, maintaining a gross margin of 61% and expanding its international sales reach.
What is TOMI's strategy for international expansion?
The company plans to escalate its presence in global markets with nearly 36% of revenue originating from international sales.
How does TOMI perform in product innovation?
Continued investment in R&D aims to broaden the applications of its SteraMist technology across multiple sectors.
What is the company's liquidity position?
Recently, TOMI secured $535,000 in financing and reported $2.5 million in working capital as of September 30, 2025.
What steps is TOMI taking to enhance its financial standing?
The company is establishing equity lines of credit, seeking to file a universal shelf registration statement to enhance its capital access.
